Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded access study of LIVMARLI for the treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC)

Next Previous
Trial Profile

An Expanded access study of LIVMARLI for the treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maralixibat (Primary)
  • Indications Alagille syndrome; Intrahepatic cholestasis
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 07 Aug 2023 New trial record
  • 25 Jul 2023 According to a Mirum Pharmaceuticals media release, the company has this expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top